JP6929010B2 - 交差架橋剤、及び関連する方法 - Google Patents

交差架橋剤、及び関連する方法 Download PDF

Info

Publication number
JP6929010B2
JP6929010B2 JP2018547415A JP2018547415A JP6929010B2 JP 6929010 B2 JP6929010 B2 JP 6929010B2 JP 2018547415 A JP2018547415 A JP 2018547415A JP 2018547415 A JP2018547415 A JP 2018547415A JP 6929010 B2 JP6929010 B2 JP 6929010B2
Authority
JP
Japan
Prior art keywords
copper
composition
treatment
keratoconus
cornea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018547415A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019511493A (ja
JP2019511493A5 (enExample
Inventor
ケイ． アンバーティ、バラムラリ
ケイ． アンバーティ、バラムラリ
ウエハラ、ヒロノリ
ムッダナ、サントッシュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Utah, University of, Research Foundation of
University of Utah Research Foundation Inc
Original Assignee
Utah, University of, Research Foundation of
University of Utah Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Utah, University of, Research Foundation of, University of Utah Research Foundation Inc filed Critical Utah, University of, Research Foundation of
Publication of JP2019511493A publication Critical patent/JP2019511493A/ja
Publication of JP2019511493A5 publication Critical patent/JP2019511493A5/ja
Priority to JP2021130408A priority Critical patent/JP2021185154A/ja
Application granted granted Critical
Publication of JP6929010B2 publication Critical patent/JP6929010B2/ja
Priority to JP2023125896A priority patent/JP2023153926A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018547415A 2016-03-08 2016-12-06 交差架橋剤、及び関連する方法 Active JP6929010B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021130408A JP2021185154A (ja) 2016-03-08 2021-08-09 交差架橋剤、及び関連する方法
JP2023125896A JP2023153926A (ja) 2016-03-08 2023-08-02 交差架橋剤、及び関連する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662305227P 2016-03-08 2016-03-08
US62/305,227 2016-03-08
PCT/US2016/065215 WO2017155580A1 (en) 2016-03-08 2016-12-06 Cross-linking agents and associated methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021130408A Division JP2021185154A (ja) 2016-03-08 2021-08-09 交差架橋剤、及び関連する方法

Publications (3)

Publication Number Publication Date
JP2019511493A JP2019511493A (ja) 2019-04-25
JP2019511493A5 JP2019511493A5 (enExample) 2020-01-23
JP6929010B2 true JP6929010B2 (ja) 2021-09-01

Family

ID=59790799

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018547415A Active JP6929010B2 (ja) 2016-03-08 2016-12-06 交差架橋剤、及び関連する方法
JP2021130408A Pending JP2021185154A (ja) 2016-03-08 2021-08-09 交差架橋剤、及び関連する方法
JP2023125896A Pending JP2023153926A (ja) 2016-03-08 2023-08-02 交差架橋剤、及び関連する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021130408A Pending JP2021185154A (ja) 2016-03-08 2021-08-09 交差架橋剤、及び関連する方法
JP2023125896A Pending JP2023153926A (ja) 2016-03-08 2023-08-02 交差架橋剤、及び関連する方法

Country Status (8)

Country Link
US (2) US11065275B2 (enExample)
EP (2) EP4324454A3 (enExample)
JP (3) JP6929010B2 (enExample)
KR (2) KR20250026890A (enExample)
AU (2) AU2016396661B2 (enExample)
CA (1) CA3016688A1 (enExample)
ES (1) ES2959242T3 (enExample)
WO (1) WO2017155580A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9622911B2 (en) 2010-09-30 2017-04-18 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use
EP2830627B1 (en) 2012-03-29 2024-05-01 Epion Therapeutics, Inc. Ocular treatment solutions, delivery devices and delivery augmentation methods
EP2830637B1 (en) 2012-03-29 2024-08-21 Epion Therapeutics, Inc. Compositions and methods for treating or preventing diseases associated with oxidative stress
CA3016688A1 (en) * 2016-03-08 2017-09-14 University Of Utah Research Foundation Ophthalmic cross-linking agents and associated methods
KR20250109788A (ko) * 2018-01-05 2025-07-17 유니버시티 오브 유타 리서치 파운데이션 근시 진행의 치료
CN113811527B (zh) 2019-01-25 2024-12-31 艾弗德罗股份有限公司 双(双吖丙啶)衍生物作为光交联剂治疗角膜扩张性疾病
US20220288114A1 (en) * 2019-07-11 2022-09-15 University Of Utah Research Foundation Multi-agent ocular formulations and treatment methods
TW202245810A (zh) * 2021-02-01 2022-12-01 美商艾維娜傳送系統公司 散光之治療
TW202302121A (zh) * 2021-02-11 2023-01-16 猶他大學研究基金會 近視之治療
CN114082960B (zh) * 2021-11-11 2023-01-17 江苏徐工工程机械研究院有限公司 轴套的制备方法、轴套及挖掘机
CN115282349A (zh) * 2022-07-05 2022-11-04 复旦大学附属眼耳鼻喉科医院 一种有利于改善孟加拉玫瑰红-绿光角膜胶原交联技术中cct降低的角膜交联试剂

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4490389A (en) * 1976-03-11 1984-12-25 Nelson Research & Development Co. Contact lens preserving solution containing ascorbic acid or salts thereof
JPH05503527A (ja) * 1990-02-22 1993-06-10 マクノート・ピーティーワイ・リミテッド 人工涙液
US5270051A (en) * 1991-10-15 1993-12-14 Harris Donald H Enzyme-orthokeratology
US5997911A (en) * 1996-08-27 1999-12-07 Brinton Veterinary Supply, Inc. Composition and method for reducing diarrhea in poultry and swine
JPH10273322A (ja) * 1997-01-30 1998-10-13 Kubota Corp 抗菌性複合チタン酸化合物およびその製造方法
BR9908692A (pt) * 1998-03-09 2001-12-04 Ista Pharmaceuticals Inc Uso de agentes de enrijecimento corneal emortocerotologia enzimática
US6231889B1 (en) * 1998-09-21 2001-05-15 Chronorx, Llc Unit dosage forms for the treatment of herpes simplex
RU2165749C1 (ru) * 2000-07-06 2001-04-27 Общество с ограниченной ответственностью "Научно-экспериментальное производство Микрохирургия глаза" Способ восстановления эндотелия роговицы
JP2004513905A (ja) * 2000-11-16 2004-05-13 ザイラー，　ケネス　ティー． 抗真菌爪用組成物および使用方法
CA2574086A1 (en) * 2004-07-21 2006-02-23 Medtronic, Inc. Medical devices and methods for reducing localized fibrosis
US20060134226A1 (en) * 2004-11-16 2006-06-22 Todd Leonard Compositions useful to treat ocular neovascular diseases and macular degeneration
US20060165611A1 (en) * 2005-01-26 2006-07-27 National Research Laboratories, Ltd. Composition for Treating and Preventing Periodontal Disease and Method of Use
US20060276777A1 (en) 2005-04-08 2006-12-07 Coroneo Minas T Corneal shaping
CN101553406B (zh) 2006-12-07 2011-05-04 太阳医药高级研发有限公司 用于施加微升量的液滴形式的液体的可计量的滴瓶
WO2008124009A2 (en) 2007-04-02 2008-10-16 The Cleveland Clinic Foundation Treating glaucoma
WO2011041309A1 (en) * 2009-09-29 2011-04-07 Arresto Biosciences, Inc Methods and compositions for treatment of ocular fibrosis
CN102100693A (zh) * 2009-12-16 2011-06-22 沈阳兴齐制药有限公司 一种含有肌肽的人工泪液及其制备方法
BRPI1002523B1 (pt) * 2010-07-14 2020-06-02 Universidade Federal De Minas Gerais Processo de síntese de complexos de cobre com atividade antitumoral
WO2014065863A1 (en) 2012-10-22 2014-05-01 The Regents Of The University Of California Compositions and methods for promoting collagen-crosslinking
RU2683651C2 (ru) * 2013-06-18 2019-04-01 Иван Дмитриевич Захаров Лекарственное средство для лечения кератоконуса и других дегенеративных заболеваний роговицы и фармацевтические препараты на его основе
DE102014012675A1 (de) 2014-08-26 2016-03-03 Wavelight Gmbh Vernetzung von Augengewebe
LT3280412T (lt) * 2015-04-09 2019-11-25 Laboratori Baldacci Spa Pirolidono karboksirūgštis (pkr), skirta naudoti oftalmologijoje
CA3016688A1 (en) * 2016-03-08 2017-09-14 University Of Utah Research Foundation Ophthalmic cross-linking agents and associated methods
KR20250109788A (ko) * 2018-01-05 2025-07-17 유니버시티 오브 유타 리서치 파운데이션 근시 진행의 치료

Also Published As

Publication number Publication date
JP2019511493A (ja) 2019-04-25
US20210322470A1 (en) 2021-10-21
AU2016396661A1 (en) 2018-09-27
US11065275B2 (en) 2021-07-20
EP3426262A1 (en) 2019-01-16
AU2023202236B2 (en) 2025-05-29
EP4324454A2 (en) 2024-02-21
AU2016396661B2 (en) 2023-01-19
KR20180119654A (ko) 2018-11-02
EP3426262C0 (en) 2023-08-23
KR20250026890A (ko) 2025-02-25
JP2023153926A (ja) 2023-10-18
JP2021185154A (ja) 2021-12-09
EP3426262B1 (en) 2023-08-23
EP3426262A4 (en) 2019-10-16
EP4324454A3 (en) 2024-05-01
US20190083529A1 (en) 2019-03-21
KR102771170B1 (ko) 2025-02-24
WO2017155580A1 (en) 2017-09-14
AU2023202236A1 (en) 2023-05-04
CA3016688A1 (en) 2017-09-14
ES2959242T3 (es) 2024-02-22

Similar Documents

Publication Publication Date Title
JP6929010B2 (ja) 交差架橋剤、及び関連する方法
US20230256012A1 (en) Treatment of myopic progression
US20100184664A1 (en) Ophthalmic compositions useful for improving visual acuity
EP3996644A1 (en) Multi-agent ocular formulations and treatment methods
RU2560669C1 (ru) Офтальмологическое средство для трансэпителиального ультрафиолетового кросслинкинга коллагена роговицы глаза
RU2513997C1 (ru) Комбинированный офтальмологический препарат в виде глазных капель, содержащий полигексаметиленгуанидин и таурин
HK40107891A (en) Cross-linking agents and associated methods
Li et al. Research progress in corneal cross-linking agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210304

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210720

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210809

R150 Certificate of patent or registration of utility model

Ref document number: 6929010

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250